# Evaxion A/S

Type: Company (EVAX)

Source: GetYourBrief — https://getyourbrief.com/entity/evaxion-as
Canonical HTML page: https://getyourbrief.com/entity/evaxion-as

## Timeline

- **2026-08-11**: Argus raises Merck price target — Argus lifts its Merck target from $130 to $145 with a Buy rating, citing pipeline depth and clinical progress.
- **2026-08-11**: Argus raises Merck price target — Argus lifts its Merck target from $130 to $145 with a Buy rating, citing pipeline depth and clinical progress.
- **2026-08-11**: Argus raises Merck price target — Argus lifts its Merck target from $130 to $145 with a Buy rating, citing pipeline depth and clinical progress.
- **2026-08-10**: Merck discloses Evaxion stake — Merck reports holding 1,214,126 shares of Evaxion A/S in a regulatory filing.
- **2026-08-10**: Merck discloses Evaxion stake — Merck reports holding 1,214,126 shares of Evaxion A/S in a regulatory filing.
- **2026-08-10**: Merck discloses Evaxion stake — Merck reports holding 1,214,126 shares of Evaxion A/S in a regulatory filing.
- **2025-09**: Merck exercises EVX-B3 option — Merck decides to in-license Evaxion's discovery-stage AI-derived vaccine candidate EVX-B3 against an undisclosed bacterial pathogen.
- **2025-09**: Merck exercises EVX-B3 option — Merck decides to in-license Evaxion's discovery-stage AI-derived vaccine candidate EVX-B3 against an undisclosed bacterial pathogen.
- **2025-09**: Merck exercises EVX-B3 option — Merck decides to in-license Evaxion's discovery-stage AI-derived vaccine candidate EVX-B3 against an undisclosed bacterial pathogen.

## Recent coverage (4 stories, network-wide)

### Merck Takes 1.2M-Share Stake in AI Vaccine Firm Evaxion
2026-08-22 13:50:46 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 2

Merck's disclosure of a 1.21 million-share stake in Evaxion A/S signals growing pharma confidence in AI-discovered vaccine candidates. For health systems, the partnership could accelerate a new class of antigen-targeted vaccines for bacterial pathogens.
Full story: https://gethealthbrief.com/story/merck-stake-evaxion-ai-vaccine-health

### Argus Lifts Merck to $145 After 1.2M Evaxion Stake
2026-08-22 13:50:37 · Sector: finance · Sentiment: Positive · Impact: 6/10 · Sources: 2

Argus raised Merck's price target to $145 on pipeline depth and M&A, while Merck disclosed a small strategic stake in Evaxion. For investors, the story is the huge gap between a mega-cap's $16.6 billion quarter and a micro-cap's cash-burning AI bet.
Full story: https://getfinancebrief.com/story/merck-evaxion-argus-price-target-stake

### Merck's EVX-B3 Option Turns 1.2M Evaxion Stake Into Validation
2026-08-22 13:50:28 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 2

Merck's option to in-license Evaxion's EVX-B3 vaccine candidate, combined with a 1.21 million-share stake, provides early validation for the biotech's AI antigen discovery platform. For biotech investors, the deal is a discovery-stage bet with long clinical timelines.
Full story: https://getbiobrief.com/story/merck-evaxion-evb3-ai-vaccine-validation

### Merck's 1.21M-Share Stake Backs AI Vaccine Discovery
2026-08-22 13:50:16 · Sector: ai · Sentiment: Positive · Impact: 6/10 · Sources: 2

Merck's stake in Evaxion is a small but meaningful validation that AI can identify viable vaccine antigens. For AI researchers, the EVX-B3 license signals pharma interest in computational biology beyond diagnostics.
Full story: https://getaibrief.com/story/merck-evaxion-ai-vaccine-discovery-validation

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.